iShares Biotechnology ETF
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1% less funds holding
Funds holding: 880 [Q2] → 875 (-5) [Q3]
6% less first-time investments, than exits
New positions opened: 79 | Existing positions closed: 84
9% less capital invested
Capital invested by funds: $5.66B [Q2] → $5.15B (-$512M) [Q3]
9% less funds holding in top 10
Funds holding in top 10: 11 [Q2] → 10 (-1) [Q3]
9.9% less ownership
Funds ownership: 76.0% [Q2] → 66.1% (-9.9%) [Q3]
24% less repeat investments, than reductions
Existing positions increased: 238 | Existing positions reduced: 314
39% less call options, than puts
Call options by funds: $496M | Put options by funds: $810M
Research analyst outlook
We haven’t received any recent analyst ratings for IBB.
Financial journalist opinion
Based on 6 articles about IBB published over the past 30 days
Positive
See It Market
1 week ago
Why Biotech Sector ETF (IBB) May Turn Bullish In 2025
One of the big themes we see emerging into 2025 is an expansion in Biotechnology and a bullish backdrop for certain biotechnology stocks.
Negative
Seeking Alpha
1 week ago
iShares Biotechnology ETF: Playing Defense
The biotech sector is very defensive and non-cyclical due to the necessity of medications and healthcare treatment being largely independent of economic growth and market risk sentiment. Money is returning to the biotech sector as displayed by increased M&A activity and financing following the pandemic-driven bubble in the sector. Biotech is a blooming area of innovation and US productivity and is expected to grow at a 14% CAGR over the next decade.
Neutral
Zacks Investment Research
1 week ago
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Neutral
Zacks Investment Research
2 weeks ago
Should You Invest in the iShares Biotechnology ETF (IBB)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05/2001.
Neutral
CNBC Television
3 weeks ago
Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation
Mizuho's Jared Holz joins 'Fast Money' to talk what's next for biopharma space after president-elect Trump names his pick for FDA head.
Positive
CNBC Television
3 weeks ago
Health care stocks jump on Trump's nominee for FDA head
CNBC's Angelica Peebles joins 'Fast Money' to talk president-elect Trump's pick for FDA head.
Positive
MarketBeat
1 month ago
Is Biotech's Bull Run Over? Examining Election Impacts
The biotech sector recently experienced a sharp reversal following a failed breakout attempt post-election. While most areas of the market surged to new heights after Donald Trump's election win on November 5, biotech ETFs like the iShares Biotechnology ETF NASDAQ: IBB and the SPDR Biotech ETF NYSE: XBI stopped short of new 52-week highs.
Neutral
CNBC Television
1 month ago
Final Trade: Euro, IBB, SMH, NEM
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Negative
See It Market
1 month ago
Key Stock Market ETFs Fall Back To Earth; What's Next?
The week right after the election, the stock market and investors were downright jubilant. This past week, the best word to describe them as is disappointed (for many outside of bitcoin investors).
Neutral
CNBC Television
1 month ago
Final Trade: West Pharma, Cameco, iShares Biotechnology ETF and Applied Digital Corp
The final trades of the day with the Fast Money traders.
Charts implemented using Lightweight Charts™